HBL- Hadasit Bio-Holdings Ltd.

As of June 30, 2026, HBL- Hadasit Bio-Holdings Ltd. carries a market capitalization of 803.92M, placing it among publicly traded companies globally. Its enterprise value stands at 833.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, HBL- Hadasit Bio-Holdings Ltd. has 11.09M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, HBL- Hadasit Bio-Holdings Ltd. maintains a current ratio of 0.52, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 12, 2026, HBL- Hadasit Bio-Holdings Ltd.'s stock has gained approximately 30.72% over the past 52 weeks. The 50-day moving average sits at 67.97, while the 200-day moving average is 47.13.

As of June 30, 2026, HBL- Hadasit Bio-Holdings Ltd. holds 70.20M in cash and equivalents against 99.90M in total debt, resulting in a net debt position of 29.70M. Total book value stands at -72.20M, with working capital of -72.20M providing operational flexibility.

HBL- Hadasit Bio-Holdings Ltd.'s most recent stock split took place on January 16, 2017.